Pfizer’s Combo COVID-19 Pill Reduced Risk of Hospitalization, Death

Pfizer’s investigational antiviral, Paxlovid (07321332 plus ritonavir) cut the risk of COVID-19 associated hospitalizations and death by 89 percent compared to placebo in an interim analysis of a phase 2/3 study, the company announced Friday.
Source: Drug Industry Daily